201 related articles for article (PubMed ID: 30373751)
1. Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.
Drennan S; Chiodin G; D'Avola A; Tracy I; Johnson PW; Trentin L; Steele AJ; Packham G; Stevenson FK; Forconi F
Clin Cancer Res; 2019 Apr; 25(8):2503-2512. PubMed ID: 30373751
[TBL] [Abstract][Full Text] [Related]
2. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.
Chiodin G; Drennan S; Martino EA; Ondrisova L; Henderson I; Del Rio L; Tracy I; D'Avola A; Parker H; Bonfiglio S; Scarfò L; Sutton LA; Strefford JC; Forster J; Brake O; Potter KN; Sale B; Lanham S; Mraz M; Ghia P; Stevenson FK; Forconi F
Blood Adv; 2022 Sep; 6(18):5494-5504. PubMed ID: 35640238
[TBL] [Abstract][Full Text] [Related]
3. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
Cheng S; Ma J; Guo A; Lu P; Leonard JP; Coleman M; Liu M; Buggy JJ; Furman RR; Wang YL
Leukemia; 2014 Mar; 28(3):649-57. PubMed ID: 24270740
[TBL] [Abstract][Full Text] [Related]
4. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
5. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function.
Coelho V; Krysov S; Steele A; Sanchez Hidalgo M; Johnson PW; Chana PS; Packham G; Stevenson FK; Forconi F
Blood; 2013 Oct; 122(15):2664-72. PubMed ID: 23954894
[TBL] [Abstract][Full Text] [Related]
6. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
[No Abstract] [Full Text] [Related]
7. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
[TBL] [Abstract][Full Text] [Related]
8. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
[TBL] [Abstract][Full Text] [Related]
9. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
10. IL-4 enhances expression and function of surface IgM in CLL cells.
Aguilar-Hernandez MM; Blunt MD; Dobson R; Yeomans A; Thirdborough S; Larrayoz M; Smith LD; Linley A; Strefford JC; Davies A; Johnson PM; Savelyeva N; Cragg MS; Forconi F; Packham G; Stevenson FK; Steele AJ
Blood; 2016 Jun; 127(24):3015-25. PubMed ID: 27002119
[TBL] [Abstract][Full Text] [Related]
11. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
12. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
13. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.
Mockridge CI; Potter KN; Wheatley I; Neville LA; Packham G; Stevenson FK
Blood; 2007 May; 109(10):4424-31. PubMed ID: 17255355
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
[TBL] [Abstract][Full Text] [Related]
16. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
17. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.
Krysov S; Steele AJ; Coelho V; Linley A; Sanchez Hidalgo M; Carter M; Potter KN; Kennedy B; Duncombe AS; Ashton-Key M; Forconi F; Stevenson FK; Packham G
Blood; 2014 Nov; 124(20):3101-9. PubMed ID: 25170122
[TBL] [Abstract][Full Text] [Related]
19. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
Wodarz D; Garg N; Komarova NL; Benjamini O; Keating MJ; Wierda WG; Kantarjian H; James D; O'Brien S; Burger JA
Blood; 2014 Jun; 123(26):4132-5. PubMed ID: 24829205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
